A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 study Authors: Helena A Yu, Yasushi Goto, Pasi A Jänne Published: 2026 ABSTRACT Plain Language Summary What is this summary about? This is a summary of the publication about the HERTHENA-Lung01 study, which was published in the Journal of Clinical Oncology in September 2023. The study included 277 adults with non-small-cell lung cancer (NSCLC) that had a mutation in a gene called EGFR. The researchers wanted to know whether a study drug called HER3-DXd (patritumab deruxtecan) could improve participants’ cancer after it had grown after previous treatment with certain other cancer drugs. What are the key takeaways? About 3 out of every 10 participants responded to treatment with HER3-DXd at some point during the study, which means their cancer shrank significantly or disappeared. Among the participants who benefited, about half had their cancer continue to respond to HER3-DXd for longer than 6.4 months before growing or spreading.After starting treatment with HER3-DXd, about half of the participants lived for longer than about 5.5 months before their cancer grew, spread, or caused death, and for longer than about 11.9 months overall.For participants with brain metastases, 1 out of every 3 participants had their brain metastases respond to treatment with HER3-DXd. About half of these participants had their brain metastases continue to respond to HER3-DXd for longer than about 8 months.About 6 out of every 10 participants had a severe new medical issue during the study, either related or unrelated to HER3-DXd.Almost all participants had a new medical issue during the study that was possibly related to HER3-DXd. About 1 out of every 20 participants had interstitial lung disease (ILD) or pneumonitis that was possibly related to HER3-DXd. What were the main conclusions reported by the researchers? HER3-DXd has been shown to be effective for people who have NSCLC with certain EGFR mutations and whose cancer has progressed after multiple previous treatments. People who receive HER3-DXd should be watched closely for signs of interstitial lung disease (ILD) or pneumonitis. These are the results from one study, and other studies might provide different results. This study did not directly compare HER3-DXd with any other cancer treatments. Always talk to your doctor before making any changes to your medication. Further studies with HER3-DXd are planned and multiple studies are ongoing.Clinical trial number: NCT04619004KEYWORDS: lung cancer, cancer, patritumab deruxtecan, NSCLC, PLSP Acknowledgments Daiichi Sankyo would like to thank the clinical study participants and their family members and caregivers. They would also like to thank the staff members at the study centers who cared for the participants in the clinical study. This is an abstract of the Plain Language Summary of Publication article. View the full Plain Language Summary PDF of this article to read the full-text Link to original article here Disclosure statement Helena A. Yu reports fees from consulting or advisory roles at AstraZeneca, Daiichi Sankyo, Blueprint Medicines, Janssen, C4 Therapeutics, Cullinan Oncology, Black Diamond Therapeutics, Taiho Oncology, AbbVie; research funding from AstraZeneca (Inst), Astellas Pharma (Inst), Lilly (Inst), Novartis (Inst), Pfizer (Inst), Daiichi Sankyo (Inst), Cullinan Oncology (Inst), Janssen Oncology (Inst), Erasca, Inc (Inst), Blueprint Medicines (Inst), Black Diamond Therapeutics (Inst); and a relationship with Astellas Pharma. Yasushi Goto reports honoraria from AstraZeneca, Boehringer Ingelheim, Lilly Japan, Chugai Pharma, Taiho Pharmaceutical, Ono Pharmaceutical, MSD, Pfizer, Bristol Myers Squibb Japan, Novartis, Thermo Fisher Scientific, Merck, Guardant Health AMEA, Takeda, Daiichi Sankyo/AstraZeneca, Daiichi Sankyo/UCB Japan, Amgen, Janssen, Sandoz, Nichi-Iko; fees from consulting or advisory roles at Lilly, Boehringer Ingelheim, Taiho Pharmaceutical, Pfizer, Novartis, AstraZeneca, Chugai Pharma, Guardant Health AMEA, Daiichi Sankyo/UCB Japan, Janssen, Ono Pharmaceutical; and research funding from AbbVie (Inst), Lilly Japan (Inst), Pfizer (Inst), Ono Pharmaceutical (Inst), Daiichi Sankyo (Inst), Bristol Myers Squibb Japan (Inst), Chugai Pharma (Inst), Taiho Pharmaceutical (Inst), MSD (Inst), AstraZeneca (Inst), Novartis (Inst), Merck Serono (Inst), Genomic Health (Inst), CMIC (Inst), Takeda (Inst), EPS Holdings (Inst), IQvia (Inst), Daiichi Sankyo/UCB Japan (Inst), Janssen (Inst), Amgen (Inst), EP Croit Co (Inst), Astellas Amgen BioPharma (Inst), Bayer (Inst), Preferred Network (Inst). Pasi A. Jänne reports stock and other ownership interests with Gatekeeper Pharmaceuticals, Loxo; fees from consulting or advisory roles with Pfizer, Boehringer Ingelheim, AstraZeneca, Merrimack, Chugai Pharma, Roche/Genentech, Loxo, Mirati Therapeutics, Araxes Pharma, Ignyta, Lilly, Takeda, Novartis, Biocartis, Voronoi Health Analytics, SFJ Pharmaceuticals Group, Sanofi, Daiichi Sankyo, Silicon Therapeutics, Nuvalent, Inc, Eisai, Bayer, Syndax, AbbVie, Allorion Therapeutics, Accutar Biotech, Transcenta, Monte Rosa Therapeutics, Scorpion Therapeutics, Merus, Frontier Medicines, Hongyun Biotech, Duality Biologics; research funding from AstraZeneca (Inst), Astellas Pharma (Inst), Daiichi Sankyo (Inst), Lilly (Inst), Boehringer Ingelheim (Inst), Puma Biotechnology (Inst), Takeda (Inst), Revolution Medicines (Inst); and is a co-inventor on a DFCI-owned patent on EGFR mutations licensed to Lab Corp and receives post-marketing royalties from this invention. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing support was provided by Samuel Entwisle and Scott Finger (Center for Information & Study on Clinical Research Participation), and funded by Daiichi Sankyo Company, Limited and Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Editorial support was provided in accordance with Good Publication Practice guidelines (https://ismpp.org/gpp-2022). Patient reviewers on this PLSP have received honorarium from Future Oncology for their review work but have no other relevant financial relationships to disclose. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose. Author contributions All authors and sponsors assisted in data interpretation, writing the report, reviewing the manuscript, and providing final approval to submit the manuscript for publication. Funding This manuscript was funded by Daiichi Sankyo, Ltd, who provided assistance with writing and reviewing the manuscript.